Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 4/20 | 0.54 |
| ▸ | NPY1R | P25929 | 3/20 | 0.54 |
| ▸ | NPY2R | P49146 | 3/20 | 0.54 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.52 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266554 | 1.00 | NPY4R (0.54) | NPY4RNPY1RNPY2RENPEPERAP2 | |
| SCHEMBL30252225 | 1.00 | NPY4R (0.54) | NPY4RNPY1RNPY2RENPEPERAP2 | |
| SCHEMBL29948864 | 1.00 | NPY4R (0.54) | NPY4RNPY1RNPY2RENPEPERAP2 | |
| SCHEMBL4293347 | 1.00 | NPY4R (0.54) | NPY4RNPY1RNPY2RENPEPERAP2 | |
| SCHEMBL29365741 | 1.00 | NPY4R (0.54) | NPY4RNPY1RNPY2RENPEPERAP2 | |
| SCHEMBL4293356 | 1.00 | NPY4R (0.54) | NPY4RNPY1RNPY2RENPEPERAP2 | |
| SCHEMBL4420809 | 0.98 | ENPEP (0.56) | NPY4RNPY1RNPY2RENPEPERAP2 | |
| SCHEMBL5032917 | 0.97 | ENPEP (0.56) | NPY4RNPY1RNPY2RENPEPERAP2 | |
| SCHEMBL31467474 | 0.97 | ERAP2 (0.55) | NPY4RNPY1RNPY2RENPEPERAP2 | |
| SCHEMBL27906634 | 0.94 | ENPEP (0.52) | NPY4RNPY1RNPY2RENPEPERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282878-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANTIGEN BINDING ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-09-11 | — | — | US | claimed |
| CN-119301105-A | Thiostrepton-based compounds for the treatment of cancer and preparation thereof | RS肿瘤学有限责任公司 | 2025-01-10 | — | — | CN | claimed |
| WO-2023212662-A2 | COMPOSITIONS AND METHODS FOR MODULATING ANTIGEN BINDING ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-11-02 | — | — | WO | claimed |
| US-11649267-B2 | Mitrecin A polypeptide with antimicrobial activity | THE MITRE CORPORATION (US) | 2023-05-16 | — | — | US | claimed |
| CN-103111093-B | The preparation of flag peptide tag recombinant protein immunoaffinity purification enriching column and application thereof | NANJING LANGUANG (BLUE LIGHT) BIOTECHNOLOGY INC. (CN) | 2015-07-29 | — | — | CN | claimed |
| CN-103111093-A | Preparation and application of flag peptide tagged recombinant protein immunoaffinity purification and enrichment column | NANNING LANGUANG BLUE LIGHT BIOTECHNOLOGY INC | 2013-05-22 | — | — | CN | claimed |
| EP-4749281-A2 | DETECTOR | UK NIVD Ltd (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260125474-A1 | Anti-CTLA-4 Binding Proteins and Methods of Use Thereof | GIGAGEN INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-3985024-B1 | ANTI-ACTIVIN-A ANTIBODY AND CHEMOTHERAPY COMBINATION FOR THE TREATMENT OF OVARIAN CANCER | ATARA BIOTHERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12595501-B2 | Expression of products from nucleic acid concatemers | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12589139-B2 | Clostridial neurotoxins comprising an exogenous activation loop | IPSEN BIOPHARM LIMITED (GB) | 2026-03-31 | — | — | US | disclosed |
| US-20260049985-A1 | Localized Surface Plasmon Resonance Detector | UK NIVD LTD (GB) | 2026-02-19 | — | — | US | disclosed |
| US-12545728-B2 | Treatment of cancer metastasis by targeting exosome proteins | LONZA SALES AG (CH) | 2026-02-10 | — | — | US | disclosed |
| EP-1379266-A4 | MODIFIED ANNEXIN PROTEINS AND METHODS FOR PREVENTING THROMBOSIS | SURROMED INC (US) | 2004-05-06 | — | — | EP | disclosed |
| WO-2004013303-A2 | MODIFIED ANNEXIN PROTEINS AND METHODS FOR TREATING VASO-OCCLUSIVE SICKLE-CELL DISEASE | SURROMED, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| EP-1379266-A2 | MODIFIED ANNEXIN PROTEINS AND METHODS FOR PREVENTING THROMBOSIS | SurroMed, Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030166532-A1 | Modified annexin proteins and methods for preventing thrombosis | SURROMED, INC. | 2003-09-04 | — | — | US | disclosed |
| WO-2002067857-A3 | MODIFIED ANNEXIN PROTEINS AND METHODS FOR PREVENTING THROMBOSIS | SURROMED INC (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002067857-A2 | MODIFIED ANNEXIN PROTEINS AND METHODS FOR PREVENTING THROMBOSIS | SURROMED, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| CN-1355842-A | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY INC (US) | 2002-06-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589139-B2 | Clostridial neurotoxins comprising an exogenous activation loop | PDXK, VIP, F13B | NPY4R 133/4885NPY1R 26/4885NPY2R 115/4885 |
| US-20260125474-A1 | Anti-CTLA-4 Binding Proteins and Methods of Use Thereof | CD274, MICA, PDCD1LG2 | NPY4R 294/4885NPY1R 315/4885NPY2R 792/4885 |
| US-12545728-B2 | Treatment of cancer metastasis by targeting exosome proteins | ENPP3, ENTPD3, ENTPD2 | NPY4R 3019/4885NPY1R 3401/4885NPY2R 3197/4885 |
| US-20260049985-A1 | Localized Surface Plasmon Resonance Detector | SHBG, FCGR3B, LGALS3BP | NPY4R 352/4885NPY1R 226/4885NPY2R 542/4885 |
| US-12595501-B2 | Expression of products from nucleic acid concatemers | SRRT, TELO2, INCENP | NPY4R 1621/4885NPY1R 667/4885NPY2R 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.